RUXIENCE 10 MG
RITUXIMAB : 10 MG · DIN 02495724 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is RUXIENCE?
RUXIENCE 10 MG contains RITUXIMAB : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02495724, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-May-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02495724 |
|---|---|
| Brand name | RUXIENCE |
| Generic / active ingredient | RITUXIMAB : 10 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | L01FA01 RITUXIMAB |
| AHFS class | 38:00.00 |
| Biosimilar | Yes |
| Health Canada status | MARKETED |
| Status date | 26-May-2020 |
What can be used instead?
Other Canadian products sharing ATC code L01FA01 RITUXIMAB. 7 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RITUXAN | 10 MG | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02241927 |
| RITUXAN SC | 1400 MG / 11.7 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02457350 |
| RITUXAN SC | 1600 MG / 13.4 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02473976 |
| RIXIMYO | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02498316 |
| TRUXIMA | 100 MG / 10 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02478382 |
| TRUXIMA | 500 MG / 50 ML | SOLUTION | CELLTRION INC. | MARKETED | DIN 02478390 |
| RIABNI | 10 MG | SOLUTION | AMGEN CANADA INC | CANCELLED POST MARKET | DIN 02513447 |
Who else supplies RITUXIMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RITUXIMAB appears in 128 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.